FIELD: medicine, pharmaceutics.
SUBSTANCE: there are offered: the use of (S)-N-[2-(1,6,7,8-tetrahydro-2H-indeno[5,4-b]furan-8-yl)ethyl]propionamide (Ramelteon) in combination with one or more drug substances chosen from fluoxetine, sertraline, paroxetine, mianserine, milnacyprane, cytalopram, escytalopram, fluvoxamine, minaprine, duloxetine, venlafaxine, imipramine, clomipramine, doxepine, trazodone, nephazodone, amitriptyline, carbamazepine, mirtazapine, diazepam, flutazolam, lorazepam, buspirone, tandospirone, ethyl loflazepat, flutoprazepam, mexazolam, clothiazepam, ethizolam, hydroxysine, alprazolam, fludiazepam, chlorodiazepoxide, cloxazolam, clorazepat and oxazolam for making a pharmaceutical composition for prevention or treatment of depression or anxiety disorder, for prevention or treatment of depression or anxiety disorder in the patients with underlying diabetes, hyperlipidemia, hypertension or metabolic syndrome, as well as appropriate methods of treating.
EFFECT: intensified effect of diazepam or paroxetine in joint administration with Ramelteon with no adverse reactions.
4 cl, 14 dwg, 1 tbl, 5 ex
